What Happened?

Shares of biopharmaceutical company Gilead Sciences (NASDAQ: GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive developments, including successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government. 

Gilead reported that its investigational single-tablet regimen for HIV, which combined bictegravir and lenacapavir, met its primary goal in a phase III study, boosting its chances for future approval. Adding to the good news, the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved lenacapavir for preventing sexually transmitted HIV-1 infection, marking the introduction of a long-acting, six-month preventative option. Furthermore, Gilead reached a three-year agreement with the U.S. government to offer discounted pricing on existing and future medicines, including treatments for HIV, Hepatitis, and COVID-19.

After the initial pop the shares cooled down to $124.46, up 2.5% from previous close.

Is now the time to buy Gilead Sciences? Access our full analysis report here.

What Is The Market Telling Us

Gilead Sciences’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 4 months ago when the stock gained 8.7% on the news that the company reported second-quarter 2025 results that topped Wall Street's expectations and raised its full-year financial guidance. 

The biopharmaceutical company posted revenue of $7.08 billion and adjusted earnings per share (EPS) of $2.01, beating analysts' consensus estimates for both figures. Buoyed by the results, Gilead raised its full-year adjusted EPS guidance to a midpoint of $8.10. While it also slightly lifted its full-year revenue guidance to $28.5 billion, this figure remained just below what analysts were projecting. Investors appeared to focus on the earnings beat and the improved profit outlook for the year, which outweighed the more cautious signal on revenue.

Gilead Sciences is up 35.5% since the beginning of the year, and at $124.46 per share, it is trading close to its 52-week high of $128.07 from November 2025. Investors who bought $1,000 worth of Gilead Sciences’s shares 5 years ago would now be looking at an investment worth $2,126.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. Click here for access to our special report that reveals one profitable leader already riding this wave.